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Abstract
Cytokine-based cancer immunotherapies stimulate a host’s immune system to fight
cancer. In particular, interleukin-12 (IL-12), a potent pro-inflammatory cytokine, has
demonstrated the ability to eliminate tumors in a number of preclinical models. Toxicities
associated with the systemic delivery of IL-12 have precluded its use in the clinic. We are
developing a novel chitosan-based hydrogel to maintain high local concentrations of
cytokines, such as IL-12, in the tumor while minimizing its systemic dissemination. This
hydrogel was found to form spontaneously within ten seconds of mixing two proprietary
components. To increase the usefulness of the hydrogel, an efficient mixing and delivery
system is needed. We designed and evaluated a device capable of mixing two solutions
from two syringes during injection. A total of eight prototypes were created using threedimensional printers; six were printed on an Object30; one was printed on a MakerBot;
another was printed on an uPrint SE Plus. Three tests were used to determine the
effectiveness of the device. The first test was a dimensional test to check for fitting of the
syringes and needle. After passing this test, the fluid dynamics were tested using distilled
water. If the device pasted the previous tests, the third test determined the mixing ability
of the device using the novel hydrogel. After success in all three tests, the sterility of the
device became the main goal. Hydrogel formation was achieved but a better material for
the device is still under investigation.
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1. Introduction
With the rise of cancer, investigation of cures has come to the forefront of biomedical
sciences research. One method to fight off the disease is overstimulation of the immune
system. Previous research demonstrated cytokine-based cancer immunotherapies are able
to fight cancer. Interleukin-12 (IL-12) is a potent pro-inflammatory cytokine with the
ability to eliminate tumors. IL-12 activates T lymphocytes and natural killer (NK) cells to
cause recession of the tumors. A byproduct of the immune stimulation is the production
of interferon (IFN)-γ. This byproduct increases the toxicity of IL-12 treatments. Phase I
and II clinical trials determined a need for safer dosages calling for a wider therapeutic
range. For example, the treatment for renal carcinoma using 500 ng/kg/day of rhIL-12
caused two deaths. Toxicities associated with the systemic delivery of IL-12 cause grade
3 and 4 adverse events. These events have precluded its use in the clinic.1, 2
Hydrogels are hydrophilic, cross linked single chain polymers or co-polymers; the cross
linking causes them to be insoluble in water but allows them to intake 10-20 times their
molecular weight while retaining their three dimensional structure. The aqueous uptake
causes the hydrogel to mimic tissue physiology increasing patient compliance. The
integrity of the structure enables the protection of encapsulated drugs such as proteins
and peptides. Hydrogels often display biocompatible capabilities with minimal
immunogenicity for synthetic hydrogels. The biocompatibility and physical similarities
cause hydrogels to be considered the closest synthetic biomaterial replica of human
tissue. These properties make hydrogels applicable in many biomedical fields including
drug delivery. 3, 4, 5
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Hydrogel drug delivery is favorable because it allows time controlled drug release and
targeted delivery. The porosity of a hydrogel dictates the rate of drug release through
either diffusion or convection. Porosity can be controlled through the cross-link ratio of
polymers. A greater ratio decreases the porosity causing a lengthier drug release. Its
adhesive property allows the hydrogel to anchor in one place. With the hydrogel in one
location, the release of the drug is targeted toward local tissue. Some hydrogels are
deformable allowing injection but most need surgical implantation. For ease of use,
noninvasive hydrogels are desirable.2, 3, 4
There are two different mechanisms for hydrogel formation: physical and chemical.
Physical hydrogel formation is caused by molecular entanglement; a polyelectrolyte
interacts with a multivalent ion of opposite charge to cause the cross-link network.
Because entanglement is the main mechanism, these hydrogels are reversible. Chemical
hydrogel formation creates cross-linked networks through covalent bonds. These bonds
are irreversible causing permanent hydrogel formation. Both hydrogels are heterogeneous
in regard to the non-uniform density of cross-links throughout the hydrogel.6
Chitosan, a natural derivative of chitin (shrimp exoskeleton), is biocompatible,
biodegradable, and mucoadhesive. This biomolecule has shown to increase bioactivity
and local retention of cytokines such as IL-12. Along with increased potency of the
cytokine, the chitosan/IL-12 mixture is capable of generating immunological memory to
control metastasis and prevent tumor reoccurrence.2, 7
A novel chitosan-based hydrogel was developed to maintain high local concentrations of
cytokines, such as IL-12, in the tumor while minimizing its systemic dissemination. This
6

hydrogel was found to form spontaneously within ten seconds of mixing two proprietary
components. To increase the usefulness of the hydrogel, an efficient mixing and delivery
system is needed. In this project, a device capable of mixing two solutions from two
syringes during injection was designed and evaluated.7
2. Methods and Materials
2.1 Materials. The 3mL BD Luer-Lok tip disposable syringe (BD 309657) was
purchased from Fisher Scientific (Pittsburgh, PA). A 20-gage BD needle (BD 305179)
was purchased from Fisher Scientific (Pittsburgh, PA). An 18-gage BD needle (BD
305199) was purchased from Fisher Scientific (Pittsburgh, PA). The proprietary hydrogel
was created in the Laboratory of Vaccine and Immunotherapy Delivery (Fayetteville,
AR).
2.2 Three Dimensional Printers. Three printers were used to create prototypes. The first
prototypes were printed on an Object30 printer using VeroWhite, a material similar to
polypropylene (PP) created by Stratasys. Once the dimensions were correct, the
prototypes were printed with two other materials, polylactide (PLA) and acrylonitrile
butadiene styrene (ABS). The MakerBot printer was used to print the PLA prototype; the
uPrint SE Plus printed the ABS prototype.
2.3 Creation of Prototypes. The computer aided design (CAD) software, SolidWorks,
was used to create the prototypes. The prototypes consist of two male luer locks allowing
two 3mL syringes to attach to the top of the device. Channels from the 3mL syringes
allowed the two solutions to mix. The newly mixed solution exits from a needle. The
device has a female connector at the bottom where an 18- or 20-gage needle is able to
7

attach. Once the design was printed, the prototype was evaluated for fit by connecting the
syringes and needle while the fluid dynamics of the device were tested using distilled
water. If the water flowed from both syringes through the device and out of the needle
consistantly, an instant forming chitosan-based hydrogel, with a proprietary formulation,
was used to test the mixing efficiency of the device.
3. Results
3.1 Fitting the Syringes and Needle.
3.1.1 Prototype One. After printing, the fit of the syringes and needle was tested. The
first prototype was 85.52mm wide and 124.06mm tall with 99.mm separation between
the two syringe connectors (see Figure 1a). The mixing portion included 15 rotations
within 29.30mm to insure a homogenous solution (see Figure 1b). The separation and
height were too large for practical use; the syringes were too far apart to simultaneously
inject into the device (see Figure 1c).

Figure 1a. This figure is the front
view of prototype one. The
syringes connect to the top and
the needle connects to the
bottom.

Figure 1b. This figure is the
translucent front view of
prototype one. The mixing
portion of the syringe contained
15 rotations in 29.30mm.

Figure 1c. This figure is the
trimetric view of prototype one.
The syringes were too far apart
and the device was too tall.
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3.1.2 Prototype Two. A more practical design was created for the second prototype (see
Figure 2a). This design was much smaller at 40.66mm wide, 46.00mm tall, and 9.23mm
separation between the syringe connectors. The thickness of the walls was 3.00mm while
the syringe connector diameter was 16.00mm. The previous mixing component included
in the first prototype was eliminated because the fluid dynamics of the small tube would
cause natural mixing. Although the second prototype featured a more ergonomic design,
the connectors were too large to secure the syringes and needle. The thickness of the
device walls also needed modifications (see Figure 2c).

Figure 2a. This figure is the front
view of prototype two. The
connectors for the syringes and
the needle were too large.

Figure 2b. This figure is the
translucent trimetric view of
prototype two. There is no
mixing system: enough mixing
will occur in the needle.

Figure 2c. This figure is the
trimetric view of prototype two.
The thickness of device walls
needs to be decreased.

3.1.3 Prototype Three. The ergonomic separation of connectors and height of the device
were established in the second prototype and used throughout the rest of the prototypes;
all future prototypes also eliminated the mixing component (see Figure 3b). The third
prototype reduced the wall thickness to 0.40mm and connector diameter to 4.20mm (see
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Figure 3a). This design also failed to connect properly to the syringes and needle; the
connectors for this prototype were too small (see Figure 3c).

Figure 3a. This figure is the front
view of prototype three. The
connectors for the syringes and
the needle were too small.

Figure 3b. This figure is the
translucent front view of
prototype three. The small
opening causes enough mixing.

Figure 3c. This figure is the
trimetric view of prototype three.
The device wall thickness was
fixed from the previous
prototype.

3.1.4 Prototype Four. The fourth prototype kept the same wall thickness but increased
the connector diameter to 8.10mm (see Figure 4c). The geometry of the needle connector
changed from an angular connector to a vertical connector (see Figure 4b); this change
relieved SolidWorks design difficulties associated with the angular geometry. Two
different syringe connectors were designed to test the assembly of the syringe and the
device (see Figure 4c). The needle locked into the connector and the syringe locked into
the right connector; this connector had an additional angular piece to help secure the
locking mechanism. The left connector was straight making the syringe screw into the
connector continuously thus interfering with the syringe locking into the device (see
Figure 4a).
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Figure 4a. This figure is the front
view of prototype four. The right
connectors for the syringes and
the needle fit best.

Figure 4b. This figure is the
translucent front view of
prototype four. The needle
connector changed from angular
to straight.

Figure 3c. This figure is the
trimetric view of prototype four.
To decrease prototype iterations,
two different connector shapes
were printed.

3.2 Reinforcing the Needle Connector
3.2.1 Prototype Five. The fifth prototype was the same as the fourth design, but both
syringe connectors resembled the right (angular) connector (see Figure 5a). After
multiple demonstrations of the connectors and a fluid dynamic study with distilled water,
the inside needle connector component broke. The thickness of the inside wall was weak
at the interface of the two channels to one channel (see Figure 5b).

Figure 5a. This figure is the
front view of prototype five.
The syringe connectors are
the same as the right syringe
connector in prototype four.

Figure 5b. This figure is the
translucent front view of
prototype five. The clear part
represents the wall thickness.
The arrow points to the
limited wall thickness.
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3.2.2 Prototype Six. The thickness of the inside needle connector could not simply be
increased without creating a completely new design. By making the two channels connect
more quickly, the thickness of the inside connector was increased (See Figure 6). The
increase was enough to last through multiple fluid dynamic tests with distilled water. The
instant forming hydrogel was tested using the device. With pressure from the table, the
solutions were mixed enough to form the hydrogel. After a few uses, again the inside
needle connector broke. Instead of changing the device dimensions, the following
prototypes tested the strength using different printing materials.

Figure 6. This figure is the
front view of prototype six.
The clear part represents the
wall thickness. The arrow
points to the increased wall
thickness.

3.3 Material Testing
3.3.1 Prototype Seven. The first six prototypes were printed on an Object30 printer using
VeroWhite material (similar to polypropylene (PP)). The dimensional limit of the printer
is 0.1mm. In an attempt to reduce printing costs, the MakerBot Replicator 2X (from now
on referred to as the MakerBot) printer was used; this printer uses polylactide (PLA).
12

With a dimensional limit of 0.8mm, the seventh prototype was unusable because the
device was not properly printed (see Figure 7).

Figure 7. This figure is a
photo of prototype seven.
The dimensional limit of the
MakerBot was not small
enough causing inaccurate
printing.

3.3.2 Prototype Eight. Because the sixth prototype was not strong enough for multiple
uses, a stronger material was needed. For preclinical uses, a multiple-use device must be
easily sterilized. VeroWhite cannot be sterilized by either ethylene-oxide or autoclaved,
both available in the lab. Acrylonitrile butadiene styrene (ABS) can be sterilized by
ethylene-oxide. An uPrint SE Plus printer was used to create the ABS prototype. Along
with its sterility, the prototype was considerably stronger allowing many uses before
failure (see Figure 8). The prototype was rougher than the VeroWhite prototype. The
increased roughness led to increased pressure; the solutions no longer mixed into a single
channel but overflowed at the site of the syringe connector.
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Figure 8. This figure is a
photo of prototype eight. The
uPrint SE Plus printer created
a prototype made of ABS.
The material was too rough
and caused overflowing of
the hydrogel mixture.

4. Discussion
4.1 Fitting the Syringes and Needle. Except for the first prototype, the first four
prototypes were iterations of differing connector diameter and wall thickness. The device
was created for easy use in a laboratory setting and eventually a clinical setting; therefore
the ergonomics of the device was a high priority. The trouble with connector fitting was
an issue with measurements. With no prior SolidWorks experience, I learned how to use
the software through trial and error. For the first prototype, my dimensions were not
easily visualized causing a large and hardly usable device. The second and third
prototype dimensional incorrectness arose from measuring errors of the needle and
syringe and mistakes in distinguishing the radius and diameter of the connectors.
By the fourth prototype, I had hours of exposure to SolidWorks keeping me from making
novice mistakes. After using a caliber to measure the syringe and needle and confidence
in my design ability, I chose to decrease the prototype iterations by utilizing the two
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syringe connectors. There were two proposed designs for this connector. Designing the
connectors with the two different designs allowed for increased feedback because
multiple prototypes did not need printing. The angled connector gave more support and
was more appealing; the straight design on the other connector was simpler. The straight
design was strong enough, but it made the syringe continuously screw onto the connector.
This continuous screwing decreased stability. The angled connector increased the
stability of the syringe device connection because a locking affect occurred between the
female and male connector. Because proper fitting was not established for both syringes
and the needle, no fluid dynamic studies ensued.
4.2 Reinforcing the Needle Connector. At the time, I thought the fifth prototype would
be the last iteration. All parts were able to connect, and the first fluid dynamics test with
distilled water was successful. The water was able to flow from both syringes out of the
needle. After multiple tries, the inside needle connector broke. The SolidWorks drawing
gave insight to the broken connector; the wall at the interface to one connector was
meager. The inside connector thickness was critical for the needle connection; an
innovative modification was needed to add strength without directly changing the
thickness. By decreasing the distance to combine the syringe channels into one channel,
thickness was indirectly added to the interface.
The sixth prototype used this design modification. The fluid dynamics were tested again
with distilled water. With successful testing, the two components needed to create the
instant forming hydrogel were tested. When pressure from the table was applied to the
needle opening, the hydrogel formed as it came out of the needle tip. After a few more
uses of the device, it broke again. With successful creation of the hydrogel from the
15

device, printing materials became the focus of strengthening the device and making the
device sterile.
4.3 Material Testing. The first six prototypes were printed with VeroWhite on an
Object30 printer. Accessibility of the printer was the main reason the first prototypes
were printed using the Object30. Once the material of the prototype became a factor,
different printers were explored.
The MakerBot printer used PLA, a more cost effective material. This printer was also
easily accessible. One concern was the decreased dimensional limit of the printer.
Because the prototype was small and precise, the dimensional limit of the printer needed
to be on the order of a tenth of a millimeter. The seventh prototype was created using the
MakerBot and was unusable. Without even trying to connect the syringe or needle, it was
obvious the device could not be utilized.
After investigating different materials, ABS was an accessible material with greater
strength and the ability to be sterilized with ethylene-oxide. The first time the prototype
was printed one of the connectors was filled with ABS. After changing the printer
orientation from vertical to horizontal, both connectors were printed hollow. The
promising strength and sterility of the material became useless after testing the hydrogel
solutions. Both solutions overflowed from the syringe connection. We assumed the
increased roughness of the ABS prototype caused the overflow. ABS was not an ideal
material for this device.
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5. Conclusion
This study proposed creating a new medical device for the use of an injectable instant
forming hydrogel. Through this investigation, the dimensions of a mixing device for two
solutions into one mixture with immediate injection abilities were created. In the process,
eight prototypes were created. Six of the prototypes were concerned with the dimensions
of the device while the other two focused on the materials of the device.
For multiple uses, the device needs sterility capabilities. With the hydrogel forming
instantly, some hydrogel would form in the device. The sterilizing process would clean
the device of any leftover materials and keep disease from spreading. The roughness of
ABS was found to be cause problems with mixing. Another material is needed for the
device to be used.
Further studies could be conducted to determine a material suitable for the device and the
feasibility of mass-producing the device. While determining the feasibility, the market
value of the device could be determined. To increase the impact of the device, further
research could determine other applications of the mixing device in medicine.
Dimensional experimenting could lead to an optimal length of existing parts for hydrogel
formation. Because changes in the two solutions impact the hydrogel formation time, the
device could test the characteristics of different formulation times.
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